A “Vector Drain” in US Gene Therapy Development?
Year: 2008
Type: article
Abstract: There is now a significant track record for novel vectors that have been designed and tested in animal models in the United States to be first tested in the clinic abroad. The double-copy vector design developed by E. Gilboa and colleagues in New York1—and later the LASN vector designed by A.D. Miller and colleagues in Seattle2—were used in the first successful clinical studies in adenosine deaminase deficiency performed in Milan, Italy.3,4 The MFG vectors developed in the laboratory of R. Mulligan at the Whitehead Institute in Cambridge, Massachusetts,5 led to the first success in the treatment of X-linked severe combined immune deficiency in Paris.
Source: Molecular Therapy
DOI: 10.1038/mt.2008.71
Authors: Michel Sadelain, David A Williams
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2001894925